IMRX
Income statement / Annual
Last year (2023), Immuneering Corporation's total revenue was $0.00,
a decrease of 100.00% from the previous year.
In 2023, Immuneering Corporation's net income was -$53.47 M.
See Immuneering Corporation’s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
| Period Ended |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
| Operating Revenue |
$0.00
|
$316,952.00
|
$2.08 M
|
$2.31 M
|
$1.92 M
|
| Cost of Revenue |
$764,138.00 |
$158,122.00 |
$1.15 M |
$1.28 M |
$1.22 M |
| Gross Profit |
-$764,138.00 |
$158,830.00 |
$926,888.00 |
$1.03 M |
$696,739.00 |
| Gross Profit Ratio |
0 |
0.5 |
0.45 |
0.45 |
0.36 |
| Research and Development
Expenses |
$41.62 M
|
$36.27 M
|
$26.54 M
|
$15.00 M
|
$4.28 M
|
| General & Administrative
Expenses |
$16.76 M
|
$15.61 M
|
$8.27 M
|
$3.11 M
|
$2.71 M
|
| Selling & Marketing
Expenses |
-$16.74 B
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General &
Administrative Expenses |
$16.76 M
|
$15.61 M
|
$8.27 M
|
$3.11 M
|
$2.71 M
|
| Other Expenses |
$29,267.00 |
$30,053.00 |
-$127,063.00 |
$0.00 |
$0.00 |
| Operating Expenses |
$58.41 M |
$51.90 M |
$34.81 M |
$18.11 M |
$6.99 M |
| Cost And Expenses |
$58.41 M |
$52.06 M |
$35.97 M |
$19.39 M |
$8.21 M |
| Interest Income |
$3.61 M |
$1.01 M |
$169,899.00 |
$42,656.00 |
$57,660.00 |
| Interest Expense |
$0.00 |
$1.01 M |
$0.00 |
$0.00 |
$351,302.00 |
| Depreciation &
Amortization |
$352,083.00
|
$796,793.00
|
$159,072.00
|
$79,305.00
|
$18,079.00
|
| EBITDA |
-$58.06 M
|
-$51.71 M
|
-$33.89 M
|
-$16.96 M
|
-$7.34 M
|
| EBITDA Ratio |
0 |
-163.16 |
-16.29 |
-7.34 |
-3.82 |
| Operating Income Ratio
|
0
|
-163.26
|
-16.29
|
-7.39
|
-3.28
|
| Total Other
Income/Expenses Net |
$4.94 M
|
$1.23 M
|
$42,836.00
|
$42,656.00
|
-$1.42 M
|
| Income Before Tax |
-$53.47 M |
-$50.51 M |
-$33.84 M |
-$17.04 M |
-$7.71 M |
| Income Before Tax Ratio
|
0
|
-159.37
|
-16.27
|
-7.37
|
-4.02
|
| Income Tax Expense |
$2.00 |
-$1.23 M |
-$307,485.00 |
-$84,336.00 |
$351,302.00 |
| Net Income |
-$53.47 M |
-$49.28 M |
-$33.54 M |
-$17.04 M |
-$8.06 M |
| Net Income Ratio |
0 |
-155.49 |
-16.12 |
-7.37 |
-4.2 |
| EPS |
-1.88 |
-1.87 |
-1.27 |
-0.67 |
-0.32 |
| EPS Diluted |
-1.88 |
-1.87 |
-1.27 |
-0.67 |
-0.32 |
| Weighted Average Shares
Out |
$28.42 M
|
$26.39 M
|
$26.32 M
|
$25.51 M
|
$25.51 M
|
| Weighted Average Shares
Out Diluted |
$28.42 M
|
$26.39 M
|
$26.32 M
|
$25.51 M
|
$25.51 M
|
| Link |
|
|
|
|
|
